After peripheral nerve injury, Schwann cells reprogram into a c-Jun-dependent repair phenotype that supports axonal regrowth; in aged animals and after chronic denervation, repair Schwann cells instead transition into a senescent phenotype (p16INK4a-positive, low c-Jun, secreting an inhibitory senescence-associated secretory phenotype, SASP) that actively blocks axonal regeneration. Clearance of these senescent cells restores regeneration in mice, but the mechanistic basis and translational viability of this discovery remain open: what induces Schwann cell senescence in aging and chronic denervation, which senescent-cell-derived factors directly collapse growth cones, how other senescent nerve cell types contribute (including via bystander senescence), how c-Jun and p16INK4a cross-regulate the repair-to-senescent transition, and whether senolytic drugs such as ABT-263 (navitoclax) can be translated into safe and effective clinical nerve repair.

Background

Schwann cells are the glial cells of the peripheral nervous system that myelinate and support peripheral axons. When a peripheral nerve is cut, mature Schwann cells dedifferentiate into a 'repair' phenotype that clears myelin debris, secretes trophic factors, and forms Bands of Büngner — columns of aligned Schwann cells that serve as guidance tracks for regrowing axons; this reprogramming depends on the transcription factor c-Jun (Arthur-Farraj et al., 2012). Axonal regeneration nevertheless fails in two clinically important settings: advanced age and chronic denervation, where the distal nerve stump remains without axons for months before repair (a common situation given nerve gap repair delays and slow human axon growth of ~1 mm/day). This failure has long been associated with diminished c-Jun expression in Schwann cells, and restoring c-Jun genetically rescues regeneration in aged and chronically denervated mice (Wagstaff et al., 2021). Cellular senescence is a state of essentially irreversible cell-cycle arrest, often driven by the cyclin-dependent kinase inhibitors p16INK4a and p21CIP1, typically accompanied by a senescence-associated secretory phenotype (SASP) — secretion of pro-inflammatory cytokines, chemokines, and matrix-remodeling factors. Senolytics are drugs that selectively kill senescent cells, e.g., ABT-263 (navitoclax), which inhibits the anti-apoptotic proteins BCL-2/BCL-xL that senescent cells depend on. Fuentes-Flores et al. (2023, EMBO Molecular Medicine) provided the first characterization of senescent Schwann cells in injured peripheral nerves: after nerve transection in aged mice and in mice subjected to chronic denervation, repair Schwann cells lose c-Jun, upregulate p16INK4a, and acquire a SASP; conditioned medium from senescent Schwann cells collapses neuronal growth cones (the motile tips of elongating axons) and inhibits axonal extension in vitro; and eliminating senescent cells — either genetically or by systemic ABT-263 — restores c-Jun expression, reduces nerve inflammation, and improves axonal regeneration and functional recovery in both settings. Among 111 cytokines assayed, only IL-6, CCL19, and CXCL1 were consistently downregulated after senolytic treatment, and prior work showed CXCL1 can directly inhibit outgrowth of adult dorsal root ganglion (the sensory-neuron clusters whose axons project into the periphery) axons (Deftu et al., 2019); however, none of these candidates was causally proven to mediate the inhibition. The authors explicitly state that the mechanism inducing Schwann cell senescence is unclear — sustained proliferative stress from failed axon re-innervation, the associated DNA damage response, and paracrine inflammatory signals (e.g., nitric oxide and cytokines from macrophages) are all plausible but undissected — and that senescent non-Schwann cells within the nerve contribute to the damaged nerve's senescent pool, in which senescent nuclei reach up to 60% of all cells (fibroblasts, macrophages, and endothelial cells constitute a substantial share of this pool, though less than Schwann cells) and may both contribute to the inhibitory environment and induce Schwann cell senescence by a bystander effect. The reciprocal regulation between c-Jun and p16INK4a (p16 can block phosphorylation of c-Jun by JNK, the c-Jun N-terminal kinase that activates c-Jun; c-Jun in turn can repress the p16 promoter) suggests a feedforward loop locking cells into senescence, but this epistasis — the mutual dependence of the two regulators' effects — has not been directly tested in Schwann cells in vivo. Finally, senescent Schwann cell ablation is envisaged as a systemic therapy: the authors note that using FDA-approved senolytic drugs as senotherapeutics broadens the spectrum of their clinical use, while the safety and efficacy of such treatment in clinical nerve repair remain to be established.

Problem Statement

Strands (1)–(4) below are stated by Fuentes-Flores et al. (2023) and left unresolved; strand (5) develops the clinical-translation direction the authors outline for senolytic senotherapeutics:

(1) Identify the molecular mechanisms that induce senescence in Schwann cells in the aging and chronically denervated injured nerve — disentangling cell-autonomous replicative stress from the associated DNA damage response and from paracrine signals of other cell types. (2) Pinpoint the senescent-cell-derived factor(s) — among candidates including CXCL1, IL-6, and CCL19 — that directly cause growth cone collapse and axonal inhibition, and prove their role mechanistically. (3) Determine the relative contribution of senescent non-Schwann cells in the nerve (fibroblasts, macrophages, endothelial cells) to the inhibitory environment and to the induction of Schwann cell senescence via bystander effects. (4) Define the regulatory relationship between c-Jun and p16INK4a in Schwann cells, including whether a feedforward loop (p16-mediated blockade of JNK/c-Jun phosphorylation and derepression upon c-Jun decline) locks in the repair-to-senescent transition. (5) Establish the safety and efficacy of senolytic drugs such as ABT-263 (navitoclax) for peripheral nerve repair, toward the clinical translation of senotherapeutics envisaged by the authors. These strands jointly serve one objective: to explain mechanistically how senescent Schwann cells cause the regenerative failure seen in aging and chronic denervation, and to establish whether eliminating them is a safe and effective repair strategy. A resolution requires all five strands to be resolved — strands (1)–(4) at the mechanistic level and strand (5) at the preclinical level (senolytic ablation in an animal or cellular model of the aged or chronically denervated nerve together with an explicit analysis of the outstanding translational risks and unknowns, rather than clinical data); any proper subset of the five strands is partial progress, not a resolution of the stated objective.

References

  1. Fuentes-Flores A, Geronimo-Olvera C, Girardi K, Necuñir-Ibarra D, Patel SK, Bons J, Wright MC, Geschwind D, Hoke A, Gomez-Sanchez JA, Schilling B, Rebolledo DL, Campisi J, Court FA (2023) Senescent Schwann cells induced by aging and chronic denervation impair axonal regeneration following peripheral nerve injury. EMBO Molecular Medicine 15(12):e17907. DOI: 10.15252/emmm.202317907. https://doi.org/10.15252/emmm.202317907 (preprint: bioRxiv, posted 2022-12-08, DOI 10.1101/2022.12.07.519441, https://doi.org/10.1101/2022.12.07.519441)
  2. Rebolledo DL, Khan M, Melov S, Hoke A, Court FA (2026) Senescent Schwann cells as therapeutic targets in nerve regeneration and peripheral neuropathies. Trends in Molecular Medicine 32(7):640-657. DOI: 10.1016/j.molmed.2026.01.003. https://doi.org/10.1016/j.molmed.2026.01.003
  3. Wagstaff LJ, Gomez-Sanchez JA, Fazal SV, Otto GW, Kilpatrick AM, Michael K, Wong LYN, Ma KH, Turmaine M, Svaren J, Gordon T, Arthur-Farraj P, Velasco-Aviles S, Cabedo H, Benito C, Mirsky R, Jessen KR (2021) Failures of nerve regeneration caused by aging or chronic denervation are rescued by restoring Schwann cell c-Jun. eLife 10:e62232. DOI: 10.7554/eLife.62232. https://doi.org/10.7554/eLife.62232
  4. Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Banerjee A, Woodhoo A, Jenkins B, Rahman M, Turmaine M, Wicher GK, Mitter R, Greensmith L, Behrens A, Raivich G, Mirsky R, Jessen KR (2012) c-Jun Reprograms Schwann Cells of Injured Nerves to Generate a Repair Cell Essential for Regeneration. Neuron 75(4):633-647. DOI: 10.1016/j.neuron.2012.06.021. https://doi.org/10.1016/j.neuron.2012.06.021
  5. Deftu AT, Ciorescu R, Gheorghe RO, Mihăilescu D, Ristoiu V (2019) CXCL1 and CXCL2 Inhibit the Axon Outgrowth in a Time- and Cell-Type-Dependent Manner in Adult Rat Dorsal Root Ganglia Neurons. Neurochemical Research 44(9):2215-2229. DOI: 10.1007/s11064-019-02861-x. https://doi.org/10.1007/s11064-019-02861-x
  6. Liang J, Zhang N, Li G, Zhou X, Li Z, Zhan Z, Fan J, Zheng C, Zhu Q, Qi J, Yan L (2024) Piezo1 promotes peripheral nerve fibrotic scar formation through Schwann cell senescence. Neuroscience Letters 837:137916. DOI: 10.1016/j.neulet.2024.137916. https://doi.org/10.1016/j.neulet.2024.137916
  7. Wang P, Wang R, Huo Y, Peng Y, Fu C, Hu Y, Ren Z, Mulat Y, Zhang H, Jiang D, Lin H (2025) Partial Reprogramming in Senescent Schwann Cells Enhances Peripheral Nerve Regeneration via Restoration of Stress Granule Homeostasis. Advanced Science 12(44):e11019. DOI: 10.1002/advs.202511019. https://doi.org/10.1002/advs.202511019
  8. Wang F, Zhao C, Jing Z, Wang Q, Li M, Lu B, Huo A, Liang W, Hu W, Fu X (2025) The dual roles of chemokines in peripheral nerve injury and repair. Inflammation and Regeneration 45(1):11. DOI: 10.1186/s41232-025-00375-4. https://doi.org/10.1186/s41232-025-00375-4
  9. Donovan LJ, Brewer CL, Bond SF, Laslavic AM, Pena Lopez A, Colman L, Jordan CE, Hansen LH, González OC, Pujari A, de Lecea L, Quarta M, Kauer JA, Tawfik VL (2025) Aging and injury drive neuronal senescence in the dorsal root ganglia. Nature Neuroscience 28(5):985-997. DOI: 10.1038/s41593-025-01954-x. https://doi.org/10.1038/s41593-025-01954-x
  10. Malachowski T, Raut GK, Ren Q, Mishra R, Bagchi SM, Deaver D, Luo X, Staff NP, Price TJ, Haroutounian S, Stewart SA (2026) Senescent peripheral fibroblasts initiate chemotherapy-induced peripheral neuropathy. bioRxiv preprint posted 2026-08-05. DOI: 10.64898/2026.08.04.742055. https://doi.org/10.64898/2026.08.04.742055
  11. Mehdipour M, Thakkar V, Chang S (2026) Enhancing peripheral nerve regeneration in aging: the role of Schwann cells, c-Jun, and emerging therapeutic strategies. Geroscience 48(3):4997-5018. DOI: 10.1007/s11357-025-01882-5. https://doi.org/10.1007/s11357-025-01882-5
  12. Zhou Z, Xiong R, Fu S, Su Y, Ao Q, Chen Y-C, Ao P (2026) Endogenous network modeling reveals mechanisms of repair Schwann cell decline and potential recovery targets. bioRxiv preprint posted 2026-05-13. DOI: 10.64898/2026.05.09.723972. https://doi.org/10.64898/2026.05.09.723972
  13. Kohlmeyer JL, Kaemmer CA, Umesalma S, Gourronc FA, Klingelhutz AJ, Quelle DE (2021) RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. International Journal of Molecular Sciences 22(10):5367. DOI: 10.3390/ijms22105367. https://doi.org/10.3390/ijms22105367